Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinoline
| Autor: | W J, Houlihan, P G, Munder, D A, Handley, G A, Nemecek |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
Platelet Aggregation Cell Survival Guinea Pigs Antineoplastic Agents Mice Inbred Strains Chick Embryo In Vitro Techniques Hemolysis Rats Sprague-Dawley Mice Dogs Tumor Cells Cultured Animals Humans Allantoin Hemodynamics Imidazoles Fibroblasts Macrophage Activation Isoquinolines Bronchodilator Agents Rats Drug Screening Assays Antitumor Neoplasm Transplantation Signal Transduction |
| Zdroj: | Arzneimittel-Forschung. 45(10) |
| ISSN: | 0004-4172 |
| Popis: | SDZ 62-434 (CAS 115621-95-9, 5-(4'-piperidinomethylphenyl)-2,3-dihydroimidazo [2,1-a]isoquinoline dihydrochloride), a member of a novel class of antitumor agents, exhibited direct and macrophage-induced cytotoxicity against a variety of murine tumor cell lines. It is more effective than edelfosine in increasing survivors and reducing tumor volume in the oral mouse Meth A fibrosarcoma model. Preliminary studies suggest that an undefined cytotoxic effect, macrophage activation and possible effects on signal transduction may account for its antitumor mechanism of action. SDZ 62-434 is currently in Phase I clinical trials as a potential antitumor agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|